Aetna modified CPB 0947 covering tagraxofusp-erzs (Elzonris) for blastic NK-cell lymphoma, effective September 26, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0947 governing tagraxofusp-erzs (Elzonris) coverage under commercial medical plans. The primary billing code at stake is J9269 — injection, tagraxofusp-erzs, 10 mcg — paired with ICD-10 diagnosis codes C86.40 and C86.41 for blastic NK-cell lymphoma. If your oncology or hematology billing team submits claims for Elzonris under Aetna commercial plans, this CPB 0947 Aetna update directly affects your workflow.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Tagraxofusp-erzs (Elzonris) — CPB 0947 |
| Policy Code | CPB 0947 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High — specialty drug with strict medical necessity criteria |
| Specialties Affected | Hematology/Oncology, Infusion Centers, Hospital Outpatient |
| Key Action | Verify J9269 prior authorization requirements and confirm C86.40 or C86.41 diagnosis coding before submitting claims after September 26, 2025 |
Aetna Tagraxofusp-erzs Coverage Criteria and Medical Necessity Requirements 2025
The Aetna tagraxofusp-erzs coverage policy under CPB 0947 covers Elzonris exclusively for blastic NK-cell lymphoma — ICD-10 codes C86.40 and C86.41. This is a narrow indication, and it reflects the drug's FDA-approved label. Don't expect coverage for off-label use under this policy.
The real issue here is medical necessity documentation. Tagraxofusp-erzs carries a serious capillary leak syndrome risk, which means the clinical record needs to show that the treating physician has evaluated the patient's fitness for this agent. Your prior authorization package must reflect that. A thin auth request gets denied.
Aetna separates its commercial criteria from Medicare criteria in this CPB. If you're billing for Medicare Advantage members, Aetna directs you to Medicare Part B criteria separately — not to CPB 0947. Make sure your team knows which plan type each patient holds before you build the auth request. Mixing up commercial and Medicare criteria is a fast path to a claim denial.
Prior authorization is effectively guaranteed for a specialty drug at this price point. Elzonris carries a per-cycle cost that puts it firmly in the category where payers scrutinize every claim. Don't attempt to bill J9269 without an active prior auth on file.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Blastic NK-cell lymphoma, unspecified | Covered (when selection criteria are met) | J9269, C86.40 | Prior authorization required; commercial plans only |
| Blastic NK-cell lymphoma, with MHC class I-positive cells | Covered (when selection criteria are met) | J9269, C86.41 | Prior authorization required; commercial plans only |
| Off-label oncology indications | Not addressed / Not covered | — | CPB 0947 does not extend coverage beyond blastic NK-cell lymphoma |
| Medicare Advantage members | Refer to Medicare Part B criteria | — | CPB 0947 does not govern Medicare coverage — use Aetna's separate Part B step criteria |
Aetna Tagraxofusp-erzs Billing Guidelines and Action Items 2025
The Aetna tagraxofusp-erzs billing guidelines require precise execution. Here's what your team needs to do before and after the September 26, 2025 effective date.
| # | Action Item |
|---|---|
| 1 | Confirm the diagnosis code before you build the auth. Only C86.40 and C86.41 support J9269 reimbursement under CPB 0947. If the pathology report uses a broader lymphoma classification, work with the treating physician to confirm the blastic NK-cell lymphoma diagnosis is clearly documented and coded correctly. |
| 2 | Submit prior authorization before the first infusion — not after. J9269 is a high-cost injection code. Aetna will not pay retroactively for a specialty drug administered without an active auth. Get the auth in place before the patient starts treatment. |
| 3 | Separate commercial plan patients from Medicare Advantage patients in your workflow. CPB 0947 covers commercial plans only. Medicare Advantage members follow Aetna's Part B step criteria. Build this split into your intake process so your team doesn't use the wrong criteria set. |
| 4 | Pair J9269 with the correct chemotherapy administration CPT code. Tagraxofusp-erzs is given as an IV infusion. Your charge capture should include the appropriate code from the CPT 96401–96450 range based on the administration method and time. The policy lists this full range as related codes — pick the one that matches how your facility actually delivers the infusion. |
| 5 | Audit your documentation for capillary leak syndrome monitoring. Aetna's medical necessity review will look at whether the patient was monitored appropriately given the drug's known risk profile. Make sure your clinical notes reflect pre-infusion weight, blood pressure, and albumin checks. Gaps here create denial risk on post-payment audits. |
| 6 | If you're unsure how the modified criteria apply to active patients mid-cycle, loop in your compliance officer before the September 26, 2025 effective date. Policy modifications on specialty drugs occasionally shift criteria mid-treatment in ways that affect ongoing authorizations. Don't assume a current auth covers new criteria without verifying. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Tagraxofusp-erzs Under CPB 0947
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J9269 | HCPCS | Injection, tagraxofusp-erzs, 10 mcg |
J9269 is the billing anchor for this drug. Every unit billed represents 10 mcg. Confirm the ordered dose against the patient's weight and the authorized dose in your prior auth before submitting. Unit miscounts on specialty drug claims are a common source of claim denial and take weeks to resolve.
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C86.40 | Blastic NK-cell lymphoma, unspecified |
| C86.41 | Blastic NK-cell lymphoma, with MHC class I-positive cells |
One of these two codes must appear on every J9269 claim. If neither code is present, Aetna has no basis to approve coverage under CPB 0947. This isn't a gray area — it's a binary requirement.
A Note on What This Policy Doesn't Tell You
The published CPB 0947 summary is thin on specifics. It confirms the covered indication and the applicable codes, but it doesn't spell out every clinical criterion Aetna's reviewers apply during prior authorization. That's not unusual for a modified policy — the criteria details often live in Aetna's internal clinical guidelines, not the public-facing CPB summary.
That gap matters. When your prior auth gets a medical necessity denial, the denial reason often cites internal criteria that weren't visible in the CPB. Pull the full policy text from Aetna's provider portal and compare it against the previous version. The changes between versions tell you exactly what the reviewers are now looking for.
If you don't have access to line-by-line policy version comparisons, you're working blind on denials. That's where PayerPolicy tools close the gap.
Get the Full Picture for CPT 96401
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.